The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis

Nagaoka, Yume; Tanaka, Yoshiko; Yoshimoto, Hiroshi; Suzuki, Rie; Ryu, Kakei; Ueda, Makoto; Akiyama, Minako; Nagai, Miho; Miyaoka, Yoshitaka; Kanda, Eiichiro; Iwai, S; Nagaoka, Michio; Kanno, Yoshihiko

doi:10.1111/hdi.12620

Cited by 12 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of a new trial (Effect of Xanthine Oxidase Inhibitor in Chronic Heart Failure Patients Complicated with Hyperuricemia study – Excited-UA) study carried out on heart failure patients are soon expected [68]. Topiroxostat has also been demonstrated to significantly and safely decrease SUA levels in hyperuricemic patients receiving hemodialysis at the minimum dose compared to allopurinol ones [69]. Moreover, since topiroxostat is not dialyzable, unlike the other XOIs, the dose reduction is not required even in patients with lowered renal function [70].…”

Section: Xo Inhibitorsmentioning

confidence: 99%

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

et al. 2020

View full text Add to dashboard Cite

This review aim is to critically resume the available clinical evidence supporting the treatment of chronic hyperuricemia with xanthine-oxidase inhibitor activity. For this reason, all of the studies published in English language from 2000 to August 2019 on uric acid-lowering drugs have been carefully reviewed. The terms “serum uric acid”, “xanthine oxidase”, “allopurinol”, “febuxostat”, and “topiroxostat” have been incorporated into an electronic search strategy, alone and in combinations, in both MEDLINE (National Library of Medicine, Bethesda, MD) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). Even if new urate lowering drugs seem of particular efficacy for acute treatment of refractory hyperuricemia, their use is supported by relatively small clinical evidence: On the contrary, large long-term clinical trials have clearly demonstrated that xanthine oxidase inhibitors (namely, allopurinol and febuxostat) are effective, safe and relatively well-tolerated in the most part of patients. They have been largely tested in elderly, in patients affected by crhonic diseases such as heart failure and cancer, and in patients taking a large number of drugs, confirming their safety profile. Recent data also show that they could exert some positive effects on vascular health, renal function and glucose metabolism. Their cost is also low. In conclusion, xanthine oxidase inhibitors remain the first choice uric acid lowering drug for chronic treatment.

show abstract

Section: Xo Inhibitorsmentioning

confidence: 99%

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Febuxostat is also presumed to inhibit the same enzymatic center [6]. It was reported that topiroxostat 60 mg/day provided sUA-lowering e cacy as well as febuxostat 40 mg/day in CKD patients [7]. It was also reported that topiroxostat 20 mg/day lowered sUA in most of the patients even with advanced CKD [8].…”

Section: Discussionmentioning

confidence: 99%

Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

Kimura

Yamada

Tanemoto

2022

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration has been recommended to prevent its recurrence. We present a case whose hyperuricemia was resistant to a xanthine oxidase inhibitor, febuxostat, but not another inhibitor, topiroxostat, while both are presumed to inhibit the same enzymatic center of this rate-limiting enzyme for uric acid production. The different e cacy indicates that xanthine oxidase inhibitors are not interchangeable even among those acting on the same site of the enzyme.

show abstract

“…Дослідження FOCUS продемонструвало послідовне стабільне зниження концентрації СК під впливом фебуксостату: у перший рік лікування цільового рівня досягли 78% пацієнтів, на другий рік -76%, на третій та четвертий роки -84 та 90% відповідно; протягом перших 2 років знизилися потреба у протизапальній терапії та частота загострень. У 76,9% хворих, які мали на момент включення в дослідження тофуси, через 4 роки констатовано їхнє повне розсмоктування [27]. У 2019р.…”

Section: вступunclassified

Modern View on Anti-Inflammatory and Urat-Lowering Therapy for Gout

Tkachenko,

Babanina,

Volchenko

et al. 2023

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

This article provides a thorough analysis of new and promising pharmaceuticals for the treatment of gout, encompassing anti-inflammatory and urate-lowering therapies. It covers drugs that have already received regulatory approval and are in active clinical use, as well as those in various stages of implementation and clinical research, showcasing their notable efficacy and safety. Additionally, the article discusses contemporary gout treatment approaches in alignment with international and domestic clinical guidelines. Emphasis is placed on the safety and efficacy of colchicine in gouty arthritis and its cardioprotective properties for patients with gout and comorbid cardiovascular disease. The article provides the information on the effectiveness of canakinumab, a new anti-inflammatory agent for the symptomatic therapy of gout. The effectiveness and safety of anakinra makes it possible to consider it as a promising alternative to the traditional approach to the anti-inflammatory therapy of gout. Rylonacept allows physicians to develop more effective treatment algorithms for those patients with gout who unsatisfactory respond to conventional therapy. The article provides a historical perspective on the use of adrenocorticotropic hormone as an anti-inflammatory agent for gout. It also highlights existing, new, and potential anti-inflammatory drugs, with a primary focus on the safety and effectiveness of febuxostat, supported by recent large randomized clinical trial results. Additionally, the article describes other medications aimed at reducing uric acid levels in the bloodstream, including uricosuric agents (such as probenecid, benzbromarone, sulfinpyrazone, lesinurad, verinurad, dotinurad, and archalofenate), xanthine oxidase inhibitors (allopurinol and topiroxostat), and pegylated uricase drugs, which may hold promise for future use in combination with primary urate-lowering therapies.

show abstract

The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis

Abstract: It is suggested that a low dose of topiroxostat decreased serum uric acid sufficiently to maintain it below 7.0 mg/dL in patients receiving hemodialysis.

Cited by 12 publications

References 24 publications

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

Modern View on Anti-Inflammatory and Urat-Lowering Therapy for Gout

Contact Info

Product

Resources

About